Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ontak denileukin diftitox: Phase II data; marketed to treat persistent or recurrent CTCL

In a U.S. Phase II trial in 41 patients, 1 of 33 evaluable patients

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE